drugset / Trial / NCT01263353

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

NCT01263353

Phase 1 Completed 36 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary neuroendocrine Tumors (NET).

Timeline

Start
2010-11
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule
Subject Pasireotide Other / unclassified